 Business Update
May 23, 2024
Klaviyo, a leading provider of digital marketing solutions, has announced that Amanda Whalen, Chief Financial Officer, will be participating in a fireside chat at the upcoming William Blair Growth Stock Conference. The conference is scheduled to take place on Thursday, June 6, 2024, at 9:00 a.m. ET (6:00 a.m. PT). T...
|
Business Update
May 23, 2024
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC to be Presented at ASCO 2024 Agenus Inc. (Nasdaq: AGEN), a recognized leader in the development of innovative immunological therapies to combat cancer, has announced compelling new data surrounding their pioneering treatment involving botensilimab and balstili...
|
Business Update
May 23, 2024
: Bicycle Therapeutics plc, a pioneering biopharmaceutical company, has developed a novel class of therapeutics based on proprietary bicyclic peptide (Bicycle) technology. The company has recently disseminated promising Phase 1/2 clinical trial results for its lead Bicycle Toxin Conjugates (BTC) molecules, BT8009 an...
|
|
 Clinical Study
May 23, 2024
Coherus s Innovative Antibodies Show Potential in the Treatment of Cancer: A Closer Look at CHS-114, LOQTORZI, and CasdozokitugThe field of oncology is constantly evolving, with new therapeutic options emerging to combat various types of cancer. Coherus, a leading biopharmaceutical company, has recently presented pr...
 Business Update
May 23, 2024
BOSTON Verastem Oncology (Nasdaq: VSTM), an innovative biopharmaceutical company dedicated to developing and advancing new medicines for cancer patients, today heralded the initial interim safety and efficacy results from their ongoing RAMP 205 Phase 1/2 clinical trial. This groundbreaking trial evaluates the effe...
|
|
Our most Popular Articles
|
Business Update
August 20, 2024
In a major milestone that promises to revolutionize contact center operations, a leading healthcare provider has significantly expanded its deployment of the Verint Interaction Wrap Up Bot. Originally implemented with a modest 300 agents earlier this year, the AI-powered bot is now set to streamline workflow for an ...
|
Business Update
June 13, 2024
Mayville Engineering Company Maintains Reign as 1 Fabricator in the U.S. for 14th Year in a RowMayville Engineering Company (MEC) has once again secured the top spot as the nation s largest fabricator, according to Fabricator Magazine. This impressive achievement marks the fourteenth consecutive year that MEC has be...
|
Clinical Study
July 23, 2024
Enlivex Achieves Regulatory Milestone with Phase I Trial Authorization for Allocetraâ„¢ in Psoriatic Arthritis PatientsEnlivex Therapeutics Ltd, a clinical-stage immunotherapy company, has received regulatory authorization to initiate a Phase I clinical trial to evaluate its novel therapy, Allocetraâ„¢, in patients...
|
|
|
Company News
|
Business Update
May 23, 2024
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC to be Presented at ASCO 2024 Agenus Inc. (Nasdaq: AGEN), a recognized leader in the development of innovative immunological therapies to combat cancer, has announced compelling new data surrounding their pioneering treatment involving botensilimab and balstili...
|
Business Update
May 23, 2024
: Bicycle Therapeutics plc, a pioneering biopharmaceutical company, has developed a novel class of therapeutics based on proprietary bicyclic peptide (Bicycle) technology. The company has recently disseminated promising Phase 1/2 clinical trial results for its lead Bicycle Toxin Conjugates (BTC) molecules, BT8009 an...
|
Clinical Study
May 23, 2024
Elicio Therapeutics, a clinical-stage biotechnology company focused on developing innovative immunotherapies for cancer treatment, presented preliminary data from their ongoing AMPLIFY-7P Phase 1a study of ELI-002 7P at the 2024 ASCO Annual Meeting. ELI-002 7P is an off-the-shelf investigational therapeutic cancer v...
|
|
|
Company News
 Announcement
May 23, 2024
|
Company News
 Business Update
May 23, 2024
|
Company News
 Business Update
May 23, 2024
|
More Company News
|
Business Update
May 23, 2024
|
Business Update
May 23, 2024
|
Business Update
May 23, 2024
|
Clinical Study
May 23, 2024
|
Clinical Study
May 23, 2024
|
Product Service News
May 23, 2024
|
Clinical Study
May 23, 2024
|
Clinical Study
May 23, 2024
|
Clinical Study
May 23, 2024
|
Clinical Study
May 23, 2024
|
|
|
|
Related News
|
Clinical Study
|
Clinical Study
|
|
Stocks
|
|
Clinical Study
|
|
Clinical Study
|
|
Clinical Study
|
|
|
|
Business News
|
 Clinical Study
Coherus s Innovative Antibodies Show Potential in the Treatment of Cancer: A Closer Look at CHS-114, LOQTORZI, and CasdozokitugThe field of oncology is constantly evolving, with new therapeutic options emerging to combat various types of cancer. Coherus, a leading biopharmaceutical company, has recently presented pr...
|
|
Business Update
BOSTON Verastem Oncology (Nasdaq: VSTM), an innovative biopharmaceutical company dedicated to developing and advancing new medicines for cancer patients, today heralded the initial interim safety and efficacy results from their ongoing RAMP 205 Phase 1/2 clinical trial. This groundbreaking trial evaluates the effe...
|
 Business Update
Pan American Silver Sets New Sustainability Benchmarks, Ensuring a Prosperous FutureIn a bold move towards sustainability, Pan American Silver Corp. has unveiled its highly anticipated 2023 Sustainability Report. The report highlights the company s unwavering commitment to environmental, social, and governance (ESG)...
|
 Business Update
Oklo, a leading clean power technology and nuclear fuel recycling company, has recently joined forces with Wyoming Hyperscale to provide 100 megawatts of reliable and scalable clean power to a state-of-the-art data center campus. With a non-binding letter of intent signed, the collaboration underscores Oklo s commit...
|
|
Business Update
Klaviyo, a leading provider of digital marketing solutions, has announced that Amanda Whalen, Chief Financial Officer, will be participating in a fireside chat at the upcoming William Blair Growth Stock Conference. The conference is scheduled to take place on Thursday, June 6, 2024, at 9:00 a.m. ET (6:00 a.m. PT). T...
|
Our Most Popular Articles
|
 Business Update
In a major milestone that promises to revolutionize contact center operations, a leading healthcare provider has significantly expanded its deployment of the Verint Interaction Wrap Up Bot. Originally implemented with a modest 300 agents earlier this year, the AI-powered bot is now set to streamline workflow for an ...
|
 Business Update
Mayville Engineering Company Maintains Reign as 1 Fabricator in the U.S. for 14th Year in a RowMayville Engineering Company (MEC) has once again secured the top spot as the nation s largest fabricator, according to Fabricator Magazine. This impressive achievement marks the fourteenth consecutive year that MEC has be...
|
|
Clinical Study
Enlivex Achieves Regulatory Milestone with Phase I Trial Authorization for Allocetraâ„¢ in Psoriatic Arthritis PatientsEnlivex Therapeutics Ltd, a clinical-stage immunotherapy company, has received regulatory authorization to initiate a Phase I clinical trial to evaluate its novel therapy, Allocetraâ„¢, in patients...
|
More News
|
 Business Update
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC to be Presented at ASCO 2024 Agenus Inc. (Nasdaq: AGEN), a recognized leader in the development of innovative immunological therapies to combat cancer, has announced compelling new data surrounding their pioneering treatment involving botensilimab and balstili...
|
 Business Update
: Bicycle Therapeutics plc, a pioneering biopharmaceutical company, has developed a novel class of therapeutics based on proprietary bicyclic peptide (Bicycle) technology. The company has recently disseminated promising Phase 1/2 clinical trial results for its lead Bicycle Toxin Conjugates (BTC) molecules, BT8009 an...
|
|
Clinical Study
Elicio Therapeutics, a clinical-stage biotechnology company focused on developing innovative immunotherapies for cancer treatment, presented preliminary data from their ongoing AMPLIFY-7P Phase 1a study of ELI-002 7P at the 2024 ASCO Annual Meeting. ELI-002 7P is an off-the-shelf investigational therapeutic cancer v...
|
 Announcement
In recent news, Rosen Law Firm, a renowned global investor rights law firm, has issued a reminder to individuals who purchased common stock of Doximity, Inc. (NYSE: DOCS) between February 9, 2022, and April 1, 2024. The law firm has advised investors to secure legal counsel ahead of the June 17, 2024 deadline for th...
|
|
Business Update
WisdomTree s Strategic Success and Continued Growth: A Promising Outlook for Stockholders in 2024WisdomTree, a global financial innovator, has recently published a comprehensive presentation for its stockholders, highlighting the company s track record of success and strategic momentum ahead of its 2024 Annual Meeti...
|
|
Business Update
In a major stride towards bolstering its metallics strategy, United States Steel (U.S. Steel) recently marked the successful opening of its highly anticipated direct reduced (DR)-grade pellet production facility at the Minnesota Ore Operations-Keetac Plant. With the first shipment of DR-grade pellets already confirm...
|
 Business Update
In a recent development, Exicure, Inc. (Nasdaq: XCUR), a renowned biotechnology company with a focus on developing nucleic acid therapeutics, has received a delisting determination notice from The Nasdaq Stock Market LLC (Nasdaq). The company has failed to submit its Form 10-K for the year ended December 31, 2023, w...
|
 Business Update
Enhabit Delivers Further Insights on Comprehensive Strategic Review Process: Prepares for 2024 Annual Stockholders MeetingEnhabit, Inc. (NYSE: EHAB) has recently disclosed additional information pertaining to its rigorous strategic review process, underscoring its commitment to transparency and robust corporate gov...
|
 Business Update
SOMERSET, N.J. Legend Biotech Corporation (NASDAQ: LEGN), a global leader in cell therapy, is poised to make significant strides in the treatment of multiple myeloma through groundbreaking data and strategic collaborations. The company recently announced several pivotal advancements, including new and updated dat...
|
|
Clinical Study
Kronos Bio Advances Promising Cancer Therapeutic KB-0742 with Positive Clinical Trial UpdateSan Mateo, Calif. and Cambridge, Mass., March 05, 2024 - Kronos Bio, Inc. (Nasdaq: KRON), a leader in developing innovative cancer therapeutics, recently announced significant progress in their clinical trial for KB-0742, a p...
|
 Clinical Study
NEWS HEADLINE: Sensei Biotherapeutics SNS-101 Shows Promising Clinical Activity in Phase 1 Dose Escalation StudySensei Biotherapeutics, a leading biotechnology company focused on the development of immunotherapies, has recently presented encouraging clinical data from its Phase 1 dose escalation study of SNS-101. T...
|
 Product Service News
Affimed Announces Promising Interim Results for AFM24-102 Study in EGFR Wild-Type NSCLC and Revenue Growth at ASCO 2024 Mannheim, Germany May 23, 2024 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company, has shared encouraging early efficacy and progression-free survival (PFS) results from it...
|
 Clinical Study
The field of cancer immunotherapy has seen significant advancements in recent years, with the development of novel immunotherapies that aim to harness the body s immune system to fight against cancer. One such promising immunotherapy is ragistomig, a PD-L1x4-1BB bispecific antibody, developed by I-Mab, a global biotech company. In this article, we will delve into the encouraging Phase 1 clinical data of ragistomig presented at the 2024 American Society for Clinical Oncology Annual Meeting (ASCO 2024). This data highlights the potential of ragistomig in revolutionizing cancer treatment.Background:Ragistomig, also known as ABL503, is a highly differentiated immunotherapy designed to target the programmed cell death ligand 1 (PD-L1) and 4-1BB receptors, implicated in immune evasion and tumor growth. By simultaneously engaging both receptors, ragistomig aims to enhance T-cell activity, leading to an enhanced immune response against cancer cells.
|
|
Clinical Study
Compass Therapeutics Presents Phase 1 Data for CTX-471, a Promising CD137 Agonist Antibody for Patients with Progressive Disease After PD-1/PD-L1 InhibitorsCompass Therapeutics, a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for various diseases, has recently announced t...
|
 Clinical Study
In recent years, immunotherapy has revolutionized cancer treatment by harnessing the power of the immune system to target and eliminate cancer cells. While immune checkpoint inhibitors have proven successful, recent breakthroughs in cell-based therapies have shown tremendous potential in the fight against advanced s...
|
 Clinical Study
FibroGen Showcases Clinical Breakthroughs in Cancer Therapy at ASCO 2024 and Upcoming KOL Investor Event SAN FRANCISCO, May 23, 2024 - FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company committed to pioneering therapeutic advancements for serious unmet medical needs, is celebrating a significant mi...
|
|
|
|
|
